Page last updated: 2024-11-12

am 1241

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AM 1241: a CB(2) receptor-selective agonist; no further information available 11/2001 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10141893
CHEMBL ID408430
SCHEMBL ID2030690
MeSH IDM0404883

Synonyms (42)

Synonym
C15812
3-[(2-iodo-5-nitrophenyl)carbonyl]-1-[(1-methylpiperidin-2-yl)methyl]-1h-indole
bdbm21283
am1241
(r,s)-am1241, >=98% (hplc), solid
NCGC00165726-01
am-1241 ,
CHEMBL408430
am 1241
444912-48-5
(2-iodo-5-nitrophenyl)(1-((1-methylpiperidin-2-yl)methyl)-1h-indol-3-yl)methanone
unii-dlm851l3rd
dlm851l3rd ,
(1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole)
AKOS016004972
S1544
(2-iodo-5-nitrophenyl)-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone
gtpl3316
1-((n-methyl-2-piperidinyl)methyl)-3-(2-iodo-5-nitrobenzoyl)-1h-indole
methanone, (2-iodo-5-nitrophenyl)(1-((1-methyl-2-piperidinyl)methyl)-1h-indol-3-yl)-
j1.955.911d ,
CCG-208738
(2-iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1h-indol-3-yl)methanone
SCHEMBL2030690
ZUHIXXCLLBMBDW-UHFFFAOYSA-N ,
HMS3650F09
HY-18640
CS-0011638
(r,s)-3-(2-iodo-5-nitrobenzoyl)-1-(1-methyl-2-piperidinylmethyl)-1h-indole
(r,s)-am1241
HMS3651A13
NCGC00165726-04
SW219858-1
Q4652487
SR-01000946337-1
sr-01000946337
DTXSID301017015
am_1241
SB19545
HMS3884M19
A872526
AS-82885

Research Excerpts

Treatment

ExcerptReferenceRelevance
"AM 1241 co-treatment also attenuated spinal astrocyte and microglial marker and pro-inflammatory mediator (IL-1β, TNFα) immunoreactivities in morphine-treated rats, suggesting that CB2 agonists may be useful to prevent the neuroinflammatory consequences of sustained morphine treatment."( Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.
Keresztes, A; Largent-Milnes, TM; Ren, J; Roeske, WR; Tumati, S; Vanderah, TW; Varga, EV, 2012
)
1.1

Compound-Compound Interactions

ExcerptReferenceRelevance
" Plate cloning results showed that LBH589 combined with AM1241 inhibited the proliferation of cervical cancer cells compared to individual drug."( Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway.
Qu, X; Sheng, B; Wang, W; Xia, D, 2023
)
0.91
"LBH589 combined with AM1241 activated the endoplasmic reticulum emergency pathway, DNA damage repair signaling pathway, oxidative stress and autophagy pathway, ultimately promoting the apoptosis of cervical cancer cells."( Panobinostat (LBH589) combined with AM1241 induces cervical cancer cell apoptosis through autophagy pathway.
Qu, X; Sheng, B; Wang, W; Xia, D, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
" administration, AM-1241 was detected in plasma, spleen, and kidney; its oral bioavailability was ~21%."( Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist.
Janero, DR; Makriyannis, A; Smith, DM; Wood, JT; Zvonok, AM, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" A leftward shift in the dose-response curve was observed following WIN55,212-2 relative to morphine treatment."( Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Hohmann, AG; Makriyannis, A; Rahn, EJ, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency31.62280.004023.8416100.0000AID485290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki0.28000.00020.566510.0000AID1127520
Cannabinoid receptor 1Homo sapiens (human)IC50 (µMol)0.28000.00010.275310.0000AID323714
Cannabinoid receptor 1Homo sapiens (human)Ki1.75240.00010.50779.6000AID1127499; AID1227866; AID1798067; AID324969; AID412568; AID444910; AID569312; AID769550
Cannabinoid receptor 2 Homo sapiens (human)IC50 (µMol)0.00340.00081.58409.8000AID323715
Cannabinoid receptor 2 Homo sapiens (human)Ki0.12590.00000.415610.0000AID1127521; AID1227865; AID1798067; AID324968; AID412569; AID444909; AID569313; AID769551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 1Homo sapiens (human)EC50 (µMol)1.03800.00010.12752.2400AID1227869
Cannabinoid receptor 2 Homo sapiens (human)EC50 (µMol)6.67210.00030.15173.2800AID1227868; AID324971; AID444912
Cannabinoid receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)0.26550.00030.06660.3150AID1127523
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (40)

Assay IDTitleYearJournalArticle
AID1798067Radioligand Binding Assay from Article 10.1021/jm7011613: \\Indol-3-yl-tetramethylcyclopropyl Ketones: Effects of Indole Ring Substitution on CB2 Cannabinoid Receptor Activity.\\2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID444910Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in CHO cells2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
AID1227868Agonist activity at human CB2 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
AID444909Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK293 cells2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
AID444911Selectivity ratio of Ki for human recombinant CB1 receptor to Ki for human recombinant CB2 receptor2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
AID569314Selectivity ratio of Ki for human CB1 to Ki for human CB22011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
AID1227867Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
AID1127521Displacement of [3H]-CP55940 from human CB2 receptor expressed in HEK cells by liquid scintillation counting2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1127523Inverse agonist activity at rat CB2 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-induced cAMP accumulation2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1227869Agonist activity at human CB1 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated cAMP production2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
AID569312Displacement of [3H]CP 55940 from human CB1 receptor in cell free system2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
AID324969Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in HEK cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
AID1227871Selectivity ratio of EC50 for human CB1 receptor to EC50 for human CB2 receptor2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
AID412569Binding affinity to CB2 receptor2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
AID412568Binding affinity to CB1 receptor2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
AID739849Selectivity ratio of Ki for human recombinant CB1 receptor to Ki for human recombinant CB2 receptor2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists.
AID1127519Displacement of [3H]-CP55940 from CB2 receptor of mouse spleen membranes2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID324968Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in HEK cells2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
AID1127499Displacement of [3H]-CP55940 from human CB1 receptor by liquid scintillation counting2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID323714Binding affinity to CB1 receptor2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
AID324970Selectivity for human recombinant CB2 receptor over human recombinant CB1 receptor2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
AID444912Agonist activity at human recombinant CB2 receptor expressed in HEK293 cells coexpressing Galphaq/o5 assessed as calcium mobilization by FLIPR assay2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity.
AID412570Selectivity ratio of Ki for CB1 receptor to Ki for CB2 receptor2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow.
AID769550Binding affinity to CB1 receptor (unknown origin)2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID569313Displacement of [3H]CP 55940 from human CB2 receptor in cell free system2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
AID769551Binding affinity to CB2 receptor (unknown origin)2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID362234Antiallodynic activity in AM-630-pretreated ip dosed spinal nerve ligated Sprague-Dawley rat model assessed as inhibition of tactile allodynia2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID323715Binding affinity to CB2 receptor2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
AID1227865Displacement of [3H]CP55940 from human CB2 receptor expressed in CHO-K1 cell membrane by competitive displacement assay2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
AID324971Agonist activity at human recombinant CB2 receptor expressed in HEK cells assessed as calcium mobilization by FLIPR2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
AID769549Selectivity ratio of Ki for CB1 receptor (unknown origin) to Ki for CB2 receptor (unknown origin)2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Contributions of academic laboratories to the discovery and development of chemical biology tools.
AID1227866Displacement of [3H]CP55940 from human CB1 receptor expressed in CHO-K1 cell membrane by competitive displacement assay2015Bioorganic & medicinal chemistry letters, Jan-01, Volume: 25, Issue:1
Novel azoles as potent and selective cannabinoid CB2 receptor agonists.
AID1127573Selectivity for human CB2 receptor over human CB1 receptor2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1127520Displacement of [3H]-CP55940 from CB1 receptor of rat brain2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1346728Human CB2 receptor (Cannabinoid receptors)2006British journal of pharmacology, Sep, Volume: 149, Issue:2
In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's28 (32.56)29.6817
2010's47 (54.65)24.3611
2020's11 (12.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.68 (24.57)
Research Supply Index4.50 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index22.84 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (3.37%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other86 (96.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]